Wall Street brokerages expect that Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) will announce earnings of $0.22 per share for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Amphastar Pharmaceuticals’ earnings. The highest EPS estimate is $0.23 and the lowest is $0.20. Amphastar Pharmaceuticals reported earnings of $0.15 per share in the same quarter last year, which indicates a positive year-over-year growth rate of 46.7%. The company is scheduled to report its next earnings results on Friday, November 5th.
On average, analysts expect that Amphastar Pharmaceuticals will report full-year earnings of $0.95 per share for the current financial year, with EPS estimates ranging from $0.91 to $0.99. For the next year, analysts expect that the business will post earnings of $1.26 per share, with EPS estimates ranging from $1.16 to $1.34. Zacks’ EPS calculations are an average based on a survey of analysts that follow Amphastar Pharmaceuticals.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its quarterly earnings results on Sunday, August 8th. The company reported $0.21 earnings per share for the quarter, meeting the consensus estimate of $0.21. Amphastar Pharmaceuticals had a return on equity of 8.01% and a net margin of 2.72%.
Shares of NASDAQ AMPH traded up $0.04 during midday trading on Friday, hitting $18.02. 741 shares of the stock traded hands, compared to its average volume of 199,354. The firm has a 50-day moving average of $19.75 and a two-hundred day moving average of $19.09. The firm has a market capitalization of $865.54 million, a P/E ratio of 85.62 and a beta of 0.74. The company has a debt-to-equity ratio of 0.07, a quick ratio of 1.71 and a current ratio of 2.50. Amphastar Pharmaceuticals has a one year low of $16.91 and a one year high of $21.63.
In other Amphastar Pharmaceuticals news, EVP Yakob Liawatidewi sold 31,524 shares of the stock in a transaction on Thursday, July 15th. The stock was sold at an average price of $20.01, for a total value of $630,795.24. Following the completion of the sale, the executive vice president now owns 77,927 shares in the company, valued at approximately $1,559,319.27. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Rong Zhou sold 6,000 shares of the stock in a transaction on Monday, July 26th. The stock was sold at an average price of $20.87, for a total value of $125,220.00. Following the completion of the sale, the executive vice president now owns 92,244 shares of the company’s stock, valued at approximately $1,925,132.28. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 52,711 shares of company stock worth $1,066,412. 28.40% of the stock is owned by insiders.
Several institutional investors have recently modified their holdings of the company. BlackRock Inc. grew its position in shares of Amphastar Pharmaceuticals by 3.3% during the first quarter. BlackRock Inc. now owns 7,377,178 shares of the company’s stock valued at $135,150,000 after purchasing an additional 233,012 shares in the last quarter. Federated Hermes Inc. grew its position in shares of Amphastar Pharmaceuticals by 6.7% during the first quarter. Federated Hermes Inc. now owns 3,441,367 shares of the company’s stock valued at $63,046,000 after purchasing an additional 215,484 shares in the last quarter. Dimensional Fund Advisors LP grew its position in shares of Amphastar Pharmaceuticals by 0.4% during the second quarter. Dimensional Fund Advisors LP now owns 1,695,893 shares of the company’s stock valued at $34,189,000 after purchasing an additional 6,804 shares in the last quarter. State Street Corp grew its position in shares of Amphastar Pharmaceuticals by 2.5% during the second quarter. State Street Corp now owns 1,439,931 shares of the company’s stock valued at $29,029,000 after purchasing an additional 34,978 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its position in shares of Amphastar Pharmaceuticals by 17.4% during the second quarter. Goldman Sachs Group Inc. now owns 844,062 shares of the company’s stock valued at $17,017,000 after purchasing an additional 125,180 shares in the last quarter. Hedge funds and other institutional investors own 56.53% of the company’s stock.
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc engages in the development, manufacture, market, and sale of technically challenging and proprietary injectable, inhalation, and intranasal products. It operates through Finished Pharmaceutical Products and Active Pharmaceutical Ingredients Products segments. The Finished Pharmaceutical Products segment manufactures, markets, and distributes Primatene Mist, enoxaparin, naloxone, phytonadione, lidocaine, and other critical and non-critical care drugs.
Featured Story: Quick Ratio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.